NCT01853644View on ClinicalTrials.gov

Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 6, 2013

Primary Completion Date

October 2, 2018

Study Completion Date

May 11, 2021

Conditions
Recurrent Epithelial Ovarian CancerRecurrent Fallopian Tube CancerRecurrent Primary Peritoneal Cancer
Interventions
DRUG

Tivozanib

1.5 mg Given PO (orally)days 1-21 or every 28 day cycle

Trial Locations (2)

60555

CDH-Delnor Health System - Northwestern Medicine Cancer Center, Warrenville

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Northwestern University

OTHER

NCT01853644 - Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter